Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C
| Autor: | Takashi Honda, Hidenori Toyoda, Isao Takeda, Yasuhiro Hisanaga, Kazuhiko Hayashi, Takashi Kumada, Yasuhiro Sone, Seiki Kiriyama, Makoto Tanikawa, Satoshi Nakano, Keiichi Sugiyama |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Adolescent Hepatitis C virus Alpha interferon Hepacivirus Interferon alpha-2 medicine.disease_cause Gastroenterology Antiviral Agents Japan Liver Function Tests Interferon Internal medicine medicine Humans Interferon alfa Aged Retrospective Studies Hepatitis B virus Dose-Response Relationship Drug business.industry Incidence (epidemiology) Incidence Liver Neoplasms Interferon-alpha Drug Resistance Microbial General Medicine Hepatitis C Chronic Middle Aged medicine.disease Recombinant Proteins Treatment Outcome Oncology Hepatocellular carcinoma Immunology Multivariate Analysis Coinfection RNA Viral Female business medicine.drug Follow-Up Studies |
| Zdroj: | Oncology. 61(2) |
| ISSN: | 0030-2414 |
| Popis: | Objective: We evaluated the effect of dose and duration of treatment with interferon (IFN)-α on the incidence of hepatocellular carcinoma (HCC) after IFN treatment in patients with chronic hepatitis C. Methods: A total of 291 noncirrhotic patients with chronic hepatitis C without hepatitis B virus coinfection in whom hepatitis C virus (HCV) was not eradicated by IFN-α therapy were retrospectively analyzed. The incidence of HCC after IFN therapy was compared according to the total dose or duration of treatment. Results: Patients were followed up for 6–117 months after the end of IFN treatment. The duration of IFN treatment (≦24 vs. >24 weeks) had no effect on the incidence of HCC. However, the incidence of HCC was significantly lower in patients who received >500 million units of IFN as a total dose than in patients who received ≦500 million units of IFN (p = 0.0480), and the total dose of IFN (>500 million units) was an independent factor affecting the incidence of HCC (p = 0.0405). In addition, when focusing on patients whose histology was F2 or F3 before IFN treatment, the suppressive effect of the total dose of IFN (>500 million units) was emphasized (p = 0.0049 in generalized Wilcoxon test and p = 0.0178 in multivariate analysis). Conclusions: Patients with chronic hepatitis C should receive more than 500 million units of IFN when IFN is used to decrease the incidence of subsequent HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|